CASIF · CASI Pharmaceuticals, Inc.
$0.13
+0.00 (+0.93%)
At close · Jul 27
Market Cap
$2.65M
Shares
20.56M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$20.71M
-27.4%
FY2025
Net Income
-$48.06M
-22.4%
FY2025
Gross Margin
48.65%
+9.6pp
FY2025
Operating Margin
-217.3%
-78.5pp
FY2025
Diluted EPS
-$2.59
-1.2%
FY2025
Operating Cash Flow
-$20.75M
+29%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| $20.71M | $28.54M | $33.88M | $43.11M | $30.17M | $15.14M | |
| — | — | $614K | $127K | $321K | $866K | |
| — | $0 | $0 | $60K | $148K | $140K | |
| $10.64M | $17.39M | $13.83M | $15.83M | $12.56M | $9.51M | |
| $10.08M | $11.15M | $20.05M | $27.28M | $17.61M | $5.63M | |
| 48.65% | 39.06% | 59.19% | 63.28% | 58.38% | 37.2% | |
| $6.31M | $8.92M | $9.86M | $16M | $14.42M | $11.47M | |
| $18.34M | $17.87M | $16.45M | $14.33M | $14.71M | $7.82M | |
| $28.27M | $23.58M | $25.39M | $23.45M | $23.7M | $19.66M | |
| $28K | $1.06M | $1.29M | $1.21M | $1.35M | $1.29M | |
| $1.2M | $1.3M | $2.5M | $1.2M | $500K | $600K | |
| $55.08M | $50.77M | $45.13M | $61.31M | $59.13M | $58.41M | |
| -$45.01M | -$39.62M | -$25.08M | -$34.03M | -$41.52M | -$52.78M | |
| -217.3% | -138.84% | -74.03% | -78.95% | -137.62% | -348.6% | |
| -$43.81M | -$38.32M | -$22.58M | -$32.83M | -$41.02M | -$52.18M | |
| — | — | — | $0 | $2900 | $3100 | |
| $20K | $188K | $764K | $44K | $558K | $82K | |
| -$2.19M | -$1.19M | -$48K | -$846K | — | — | |
| -$45.87M | -$38.07M | -$26.29M | -$37.43M | -$35.84M | -$47.51M | |
| — | $0 | -$81K | $1.98M | $0 | $0 | |
| -$48.06M | -$39.26M | -$26.96M | -$41.01M | -$36.65M | -$48.29M | |
| -232.03% | -137.57% | -79.58% | -95.14% | -121.5% | -318.92% | |
| -$48.07M | -$39.83M | -$24.15M | -$34.17M | -$33.78M | -$43.28M | |
| USD/shares | -$2.59 | -$2.56 | -$2.02 | -$3.01 | -$2.69 | -$4.37 |
| USD/shares | -$2.59 | -$2.56 | -$2.02 | -$3.01 | -$2.69 | -$4.37 |
| shares | 18.54M | 15.34M | 13.36M | 13.65M | 13.61M | 11.05M |
| shares | 18.54M | 15.34M | 13.36M | 13.65M | 13.61M | 11.05M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2023: $3.55M in buybacks.